Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles
Gene · 2025
DOI: 10.1016/j.gene.2025.149458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene, 2025. Verfasst von Na He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China; The Second Clinical Medical College, Lanzhou University, Gansu, Ch…. Hauptthemen laut MEDLINE: Kinesins, Stomach Neoplasms, Spindle Apparatus, Oncogene Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Science and Technology Department of Gansu Province.
Abstract (Originalsprache)
Eg5, also known as KIF11, is a motor protein essential for establishing a bipolar spindle and ensuring proper chromosome congression during mitosis. It is amplified in various human cancers and serves as a critical oncogene driving tumour progression. However, the role and clinical significance of Eg5 in gastric cancer has remained elusive. In this study, we showed that Eg5 is upregulation in gastric cancer tissues and is negatively associated with patient prognosis. The ablation of Eg5 inhibits the proliferation and migration of gastric cancer cells and suppresses tumour growth in xenograft mice. Mechanistically, Eg5 ablation induces the formation of monopolar spindle, leading to cell apoptosis and consequent inhibition of tumour growth. Furthermore, Arry520 is demonstrated as a potent Eg5 inhibitor which blocks tumour growth by increasing the formation of cell monopolar spindle and inducing apoptosis. Arry520 exhibits efficiently therapeutic effects on gastric cancer in tumour organoid models, cell-derived xenografts and patient-derived xenografts (PDX) in mice. Collectively, our findings provide evidence for the oncogenic properties of the mitotic protein Eg5 and identify Arry520 as a promising strategy to combat gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China; The Second Clinical Medical College, Lanzhou University, Gansu, China.
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Oncology, Dingxi People's Hospital, Gansu, China.
- The Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, People's Republic of China.
- Department of Pathology, Gansu Provincial Maternity and Chlid-care Hospital, Lanzhou, Gansu, China.
- Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, People's Republic of China; Biobank of Tumors from Plateau of Gansu Province, Lanzhou University Second Hospital, Lanzhou, People's Republ…
Förderung
- Fundamental Research Funds for the Central Universities
- Science and Technology Department of Gansu Province
Zitieren
APA
He, N., Wei, X., Sun, R., Zhang, G., Zhao, J., Jiang, X., Long, B., Yu, Z., Shi, W., & Jiao, Z. (2025). Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles. Gene. https://doi.org/10.1016/j.gene.2025.149458
Vancouver
He N, Wei X, Sun R, Zhang G, Zhao J, Jiang X, et al. Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles. Gene. 2025. doi:10.1016/j.gene.2025.149458
BibTeX
@article{He2025,
author = {He, Na and Wei, Xinyuan and Sun, Ruofei and Zhang, Gengyuan and Zhao, Jie and Jiang, Xiangyan and Long, Bo and Yu, Zeyuan and Shi, Wengui and Jiao, Zuoyi},
title = {Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles},
journal = {Gene},
year = {2025},
doi = {10.1016/j.gene.2025.149458}
}
EUVIMED